Sitagliptin vs Trelagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Sitagliptin · Januvia

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00087516 · Phase 3 · completed

The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)

Result source: NCT00086502

Trelagliptin · Zafatek

Marketed by Teijin and partners

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT01431807 · Phase 3 · completed

This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07073768 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)

Result source: NCT02512068

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSitagliptinTrelagliptin
HbA1c, change-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
Body weight, change (kg)-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
—Not posted · NCT03940183
HbA1c below 7%49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
—Not posted · NCT03940183
Fasting plasma glucose, change-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
3-point MACE (% with event)—Not posted · NCT01529541—Not posted · NCT03940183

HbA1c, change

Sitagliptin
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
Trelagliptin
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

Body weight, change (kg)

Sitagliptin
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
Trelagliptin
—Not posted · NCT03940183

HbA1c below 7%

Sitagliptin
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
Trelagliptin
—Not posted · NCT03940183

Fasting plasma glucose, change

Sitagliptin
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
Trelagliptin
-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

3-point MACE (% with event)

Sitagliptin
—Not posted · NCT01529541
Trelagliptin
—Not posted · NCT03940183
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Sitagliptin: 4 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSitagliptinTrelagliptin
Dropout rate
74.6%100 mga
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
67.6%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
69.1%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
67.6%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
9%
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
12.9%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
3%
NCT01131182 · Phase 4 · registry result, not featured evidence
20.5%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
10.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
2.5%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1%
NCT01485614 · Phase 3 · registry result, not featured evidence
4.8%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
10.6%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.6%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
21.8%25 mgb
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
2.3%100 mga
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
4.2%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
—
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—
NCT01131182 · Phase 4 · registry result, not featured evidence
7.9%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
3.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
—
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
—100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—
NCT01485614 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
0.5%
NCT03115112 · Phase 3 · registry result, not featured evidence
—
NCT02791490 · Phase 3 · registry result, not featured evidence
14.5%25 mgb
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Serious AEs
7.7%100 mga
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
10.1%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
80%
NCT02556918 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
0%Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
0%Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02256189 · Phase 4 · registry result, not featured evidence
0%
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
3.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
2%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
3.7%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01131182 · Phase 4 · registry result, not featured evidence
3.1%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
4.7%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00686634 · Phase 4 · registry result, not featured evidence
2.7%
NCT00729326 · Phase 4 · registry result, not featured evidence
4.2%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
10.5%
NCT01485614 · Phase 3 · registry result, not featured evidence
6.5%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
6.7%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.1%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
41.8%25 mgb
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
1.8%
NCT03014479 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
100 mga
upper respiratory tract infection 13.1%
dizziness 11.5%
nasopharyngitis 9.2%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 30 more results
100 mg/100 mg
upper respiratory tract infection 15.1%
dizziness 10.5%
nasopharyngitis 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg
upper respiratory tract infection 11.4%
arthralgia 9.8%
blood glucose increased 8.9%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg/200 mg
upper respiratory tract infection 16.4%
dizziness 12.4%
influenza 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
infection 2% (placebo 2%)
headache 1% (placebo 1%)
loss of appetite 1% (placebo 0%)
NCT02556918 · Phase 4 · registry result, not featured evidence
100 mg
headache 1.6%
hypertension 1.6%
diarrhoea 0%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 15.8%
arrhythmic events 5.3%
genital infection 5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
light-headedness 7.7% (placebo 7.7%)
paresthesias 7.7% (placebo 0%)
nausea 0% (placebo 7.7%)
NCT02639637 · Phase 4 · registry result, not featured evidence
light-headedness 0% (placebo 7.7%)
nausea 0% (placebo 7.7%)
paresthesias 0% (placebo 0%)
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
rash 0% (placebo 2.8%)
NCT01859793 · Phase 4 · registry result, not featured evidence
hypoglycemia 0%
NCT02312063 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
50 mg
erythema 38.5%
hypoglycaemia 7.7%
periodontitis 7.7%
NCT02318693 · Phase 4 · registry result, not featured evidence
diarrhoea 9.3%
nausea 7.8%
upper respiratory tract infection 6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
hypoglycaemia 14%
blood glucose decreased 6%
NCT01686932 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
hyperglycemia 11.1%
pressure ulcer/skin ulcer 11.1%
hypoglycemia 3.7%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
hypoglycemia 6.9%
pneumonia 6.9%
urinary tract infection 6.9%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
headache 4.9%
dizziness 3.9%
hyperhidrosis 3.7%
NCT01131182 · Phase 4 · registry result, not featured evidence
nausea 15.7%
vomiting 10.2%
nasopharyngitis 8.7%
NCT00870194 · Phase 4 · registry result, not featured evidence
nausea 10.2%
nasopharyngitis 7.8%
headache 7%
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
nausea 37%
vomiting 20.5%
headache 12.3%
NCT00729326 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 7.8%
diarrhoea 4.5%
nausea 3.9%
NCT04017832 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.8%
nasopharyngitis 15.8%
upper respiratory tract infection 12.6%
NCT01485614 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.1%
upper respiratory tract infection 14.5%
diarrhoea 11.3%
NCT01760447 · Phase 3 · registry result, not featured evidence
hypoglycaemia 20%
upper respiratory tract infection 11.1%
abdominal pain 8.9%
NCT01760447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13%
hypoglycemia 5.2%
influenza 5.2%
NCT03115112 · Phase 3 · registry result, not featured evidence
diarrhoea 7.9% (placebo 4.8%)
NCT02791490 · Phase 3 · registry result, not featured evidence
25 mgb
nasopharyngitis 43.6% (placebo 33.3%)
fall 21.8% (placebo 10.4%)
hypoglycaemia 21.8% (placebo 14.6%)
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
viral upper respiratory tract infection 3.6%
NCT03014479 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 33 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sitagliptin

PMG 2-hr Change mg/dL -48.9 vs -2.2 placebo mg/dL @ 24wk100 mg
absolute change · mg/dL
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-56.3 vs -2.2 placebo mg/dL @ 24wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 Metformin mg/dL @ 20wk
NCT01485614 · Phase 3 · registry result, not featured evidence
-1.7 vs -39.7 Metformin mg/dL @ 54wk
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c -0.27% (n=188) @ 104wk100 mg/100 mg
absolute change · percentage points
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
-0.32% (n=81) @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.4% (n=195) @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.34% (n=83) @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3% (n=68) @ 13wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.3% (n=98) @ 13wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
8% (n=87) @ 13wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
6.2% (n=68) @ 26wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.3% (n=98) @ 26wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
8% (n=87) @ 26wk
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
-1.27% (n=183) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.51% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.15% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-0.38% (n=97) @ 20wk
NCT00870194 · Phase 4 · registry result, not featured evidence
-0.68% (n=111) @ 20wk
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
-1.3% (n=102) @ 16wk
NCT00686634 · Phase 4 · registry result, not featured evidence
-0.82% (n=190) @ 24wk
NCT03115112 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -0.1 mmol/L @ 104wk100 mg/100 mg
absolute change · mmol/L
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -1.8 mg/dL as posted
show 7 more results
-0.23 mmol/L @ 104wk*100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted
-0.32 mmol/L @ 104wk*200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5.7 mg/dL as posted
-0.23 mmol/L @ 104wk*200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted
-1.9 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-2.03 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.96 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.45 mmol/L @ 24wk
NCT03115112 · Phase 3 · registry result, not featured evidence
PMG 2-hr Change mg/dL -30.5 mg/dL @ 104wk100 mg/100 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-38.3 mg/dL @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-41.5 mg/dL @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-35.5 mg/dL @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hyperglycemia 83.5% (n=91) vs 74.7% (n=91) placebo @ 0.29wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 76 Participants as posted
show 1 more result
5.5% (n=91) vs 3.3% (n=91) placebo @ 0.29wk*
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
Persistent Hyperglycemia 63.7% (n=91) vs 64.8% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 58 Participants as posted
Glucose 148.7 vs 149.8 placebo mmol/L @ 0.29wk
absolute value · mmol/L
NCT02556918 · Phase 4 · registry result, not featured evidence
show 2 more results
154.2 vs 156.5 placebo mmol/L @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
9.5 vs 9.4 Basal Bolus mmol/L
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Hyperglycemia Ge 300 mg/dL 22% (n=91) vs 13.2% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
Severe Hypoglycemia Event Incidence 0% vs 0% placebo @ 0.29wk
event rate · count
NCT02556918 · Phase 4 · registry result, not featured evidence
show 1 more result
0% vs 0% placebo @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min -0.53 vs 0.67 Canagliflozin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Canagliflozin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence
FMD 5.8% (n=30) vs 6% (n=30) placebo @ 8wk
absolute change · percentage points
Following 8 weeks of therapy
NCT01859793 · Phase 4 · registry result, not featured evidence

+ 73 further endpoints in the CSV export.

Trelagliptin

HbA1c -0.76% (n=55) vs -0.74% (n=52) placebo @ 52wk25 mg
absolute change · percentage points
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.79 vs -0.41 placebo mmol/L @ 52wk25 mg
absolute change · mmol/L
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -14.3 mg/dL as posted
DTR-QOL 8.72 vs 6.35 Daily DPP-4 Inhibitors score @ 12wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 2 more results
8.04 vs 4.82 Daily DPP-4 Inhibitors score @ 4wk
NCT03014479 · Phase 4 · registry result, not featured evidence
8.58 vs 6.63 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 1 11.24 vs 7.83 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
10.98 vs 9.12 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 2 5.18 vs 0.39 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.94 vs 2.18 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 3 6.15 vs 4.87 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.85 vs 7.38 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 4 5.24 vs 3.85 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
8.53 vs 6.71 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTSQs 3.1 vs 1.7 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
3.1 vs 2.9 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sitagliptin's landscape · Trelagliptin's landscape